Asymptomatic Carotid Stenting Evaluated By Abbott’s ACT-I Study
This article was originally published in The Gray Sheet
Executive Summary
Abbott's ACT-I trial is the first randomized clinical trial comparing carotid stenting to endarterectomy surgery in asymptomatic, surgery-eligible patients
You may also be interested in...
Abbott’s Xact Carotid Stent To Join Guidant’s Acculink In U.S. Market
Abbott plans to focus its initial marketing of the Xact carotid stent on physicians most experienced with the device, which Abbott will launch immediately
Abbott’s Xact Carotid Stent To Join Guidant’s Acculink In U.S. Market
Abbott plans to focus its initial marketing of the Xact carotid stent on physicians most experienced with the device, which Abbott will launch immediately
Abbott ACT I debut
First patient is enrolled in firm's 50-site, 1,500 patient Asymptomatic Subjects with Significant Extracranial Carotid Occlusive Disease Trial (ACT I), Abbott announces March 31. The randomized clinical trial will compare carotid stenting to endarterectomy surgery in asymptomatic, surgery-eligible patients in support of a PMA for Mednova's self-expanding nitinol Xact carotid stent and Emboshield embolic protection device (1"The Gray Sheet" Jan. 24, 2005, p. 3)...